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How should economic information be used to in-
fluence drug usage and reimbursement in Europe?
While health economic data has increased in im-
portance over the last few years, decision-making
by regulatory authorities is not very transparent.
Authorities are hesitant to disclose the rationale
for their decisions for both political and technical
reasons. A manufacturer submitting health eco-
nomic data may claim confidentiality of pricing
and drug profile characteristics to prevent compet-
itors from gaining access to this information. As
well, most European countries do not have official
requirements for submitting health economic data,
so when it is included in pricing/reimbursement
submissions, authorities are not obliged to make
public their judgement on health economic data or
its weight in the decision-making process.
One exception was the official report by the
Dutch Health Care Council on the rationale for a
positive reimbursement decision for mycopheno-
late in 1996, which refers to a health economic
study [1]. Mycophenolate is an antirejection drug
used after renal transplantation. This report states
that reimbursement of this more expensive drug
may be justified due to a reduction of other direct
medical costs as a result of fewer rejections: fewer
other medications, and less dialysis and hospital-
ization. This is probably the first hard evidence in
Europe of the added value of health economic
evaluation contributing to reimbursement success.
A recent survey by our group indicated that
published evidence of the impact of health eco-
nomic data in the decision-making process is only
the tip of the iceberg [2]. Interviews were con-
ducted with many national decision-makers in Eu-
rope who are involved in pricing and reimburse-
ment. They were asked about requirements for
health economic data to support pricing and reim-
bursement decisions. The trend was towards an
increasing demand for this type of information
and, in several countries, to formal reporting re-
quirements in the near future (Fig. 1).
 
Current Trends in the Use of Pharmacoeconom-
ics and Outcomes Research in Europe
 
 by Drum-
mond et al. [3] represents a significant contribu-
tion to the evidence for added value of health
economic studies in Europe; it is important for this
information to be compiled as a review paper. The
findings are based on surveys and expert opinion
with only a limited number of references to offi-
cial documents in the study countries, but this is
inevitable since official requirements are still un-
der development in most of the study countries.
Their conclusion is that the value of health eco-
nomic studies varies widely according to intended
application and target audience. The most evident
impact of health economic studies is expected for
regulatory and reimbursement audiences because
of the elaboration of economic reporting require-
ments; evidence for the use of health economic
studies by other audiences remains sparse.
Although it is difficult to disentangle pricing
and reimbursement decisions, our recent overview
[2] for Europe clearly indicated that reimburse-
ment and pricing may be considered as two sepa-
rate procedures: decisions are made by different
bodies, different laws apply, different reporting
data are required, and reimbursement and pricing
are sequential decisions. Reimbursement decisions
are often based on clustering a new drug in an ex-
isting drug group followed by pricing of the drug
based on a reference price basket for neighboring
countries. This fourth hurdle in drug develop-
ment, the growing burden on manufacturers to
demonstrate the cost-effectiveness of their prod-
ucts before acceptance for reimbursement, may
have considerable consequences for all players in-
volved. In The Netherlands, for example, the de-
velopment process for health economic reporting
requirements may make them the first state in Eu-
rope to require formal health economic data re-
porting in drug reimbursement applications.
In The Netherlands, the main response to rising
costs has been the introduction of an impressive
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number of government cost containment policies
over the last decade resulting in the Drug Reim-
bursement System. This system is based on the
classification of drugs into groups of “therapeuti-
cally interchangeable” drugs (GVS) with a fixed re-
fund price based on the average list price of drugs
within the same group (cluster). If a price is set
higher than the fixed price, the patient must pay
the difference. There is no rebate when the drug
price is set below the fixed price. In 1993, it was
decided that new drugs would only be included in
the health insurance fund package if they fit into
an existing cluster or if no other medicinal treat-
ment was available for the disease concerned. Cur-
rently, an innovative drug that cannot be clustered
is put on a medication waiting list.
At the request of the Minister of Health, the
Dutch National Health Insurance Council (Ziek-
enfondsraad) tried to relax this rather stringent
measure. The Dutch Council for Health Care
(Raad van Volksgezondheid) advised the Ministry
of Health to use health economic data as a basis
for policy decision regarding inclusion of drugs
on the waiting list in the health insurance fund
package and awarding reimbursement status. The
Ziekenfondsraad was commissioned to develop
the pharmacoeconomic guidelines, which recently
have been approved by the Ministry of Health.
Execution of pharmacoeconomic studies in accor-
dance with those guidelines should permit reliable,
reproducible, and verifiable insight into the thera-
peutic value of a drug, the costs that will result
from its use, and the possible savings that will be
made compared with other drugs and/or treat-
ments. The intention was to implement official
requirements for using health economic data for
reimbursement decisions in July 1999, but imple-
mentation has been postponed until next summer.
The additional time is needed to resolve a number
of scientific, procedural, and legal issues.
The Dutch guidelines emphasize that evalua-
tions should focus on the registered indication of
drugs and consider both efficacy and effectiveness.
The ideal design to demonstrate effectiveness and
costs is a naturalistic prospective study. Since
study drugs are usually not approved for registra-
tion at the time of performance of economic stud-
ies, however, the use of prospective naturalistic
trials is limited, making submission of data on ef-
fectiveness and expected costs at the time of reim-
bursement not feasible. On the other hand, projec-
tions about a drug’s effectiveness and expected
costs can be modeled using realistic and explicit
assumptions based on data from clinical studies.
Over the next several years, most submissions
for reimbursement in countries like The Nether-
lands will likely be based on modeling since phar-
macoeconomic data were generally not required or
included in the clinical research programs of prod-
ucts now approaching launch. In addition, model-
Figure 1 Stringency of health economic
and quality of life data requirements for
pricing and reimbursement in Europe.
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ing often helps overcome the practical limitations
of prospective studies, particularly for chronic
conditions like Parkinson’s disease that may re-
quire longer-term extrapolations of drug effects. If
reimbursement of pharmaceuticals will be based
predominantly on economic data derived from
modeling studies, it is vital to scrutinize and refine
this approach carefully. Data sources for the vari-
ables in a model may be clinical trials, literature
(e.g., meta-analysis), databases, medical records,
and official tariff lists. A serious concern in the use
of a modeling study is the use of a Delphi/Expert
panel to establish information that could not be
derived from existing data sources.
On the basis of these logistical and method-
ological issues related to real life effectiveness and
cost data, temporary acceptance of an innovative
drug to the reimbursement package might be con-
sidered. A conditional acceptance would permit
initial decision-making on reimbursement based
on the cost-effectiveness of the new drug derived
from modeling data, followed by validation through
subsequent prospective data collection. This would
minimize the logistical and methodological con-
cerns related to current policy. It would also re-
duce the concern of industry that health economic
evaluation guidelines would delay product launch,
shortening the period of useful patent life and re-
ducing the return on R&D investment. New drugs
would be made available more quickly if pro-
spective data collection was not required prior to
reimbursement. On the other hand, removal of a
drug from a reimbursement package after addi-
tional prospective data were evaluated might have
ethical concerns and lead to some social unrest.
Even when guidelines address the methodologi-
cal issues, reimbursement decision-making will not
only be based on the findings presented in the sub-
mitted health economic data. There are two rea-
sons that these decisions will be at least partially
political. First, guidelines prescribe proper execu-
tion of health economic evaluations but not cut-off
points for approving reimbursement. Researchers
may advise on interpretation of a cost per quality-
adjusted life year (QALY), but the decision about
how much society will pay for increased effective-
ness is political. The requirements for using health
economic data for reimbursement decisions can only
be implemented when decision-making is trans-
parent and based on objective predefined criteria.
Second, policy on budgetary constraints should
be defined a priori. The Dutch authorities will also
assess the impact on macro costs for the national
health care budget by means of financial analysis.
 
The financial analysis is not part of the pharmaco-
economic research, but is based on data from eco-
nomic evaluations and descriptive epidemiology
(disease incidence and prevalence). Consequently,
if an equal cost-effectiveness score was achieved
(i.e., the same sum per life-year gained) for two
new drugs in different therapeutic categories, the
financial analysis would show a preference for
treating the disease with lower incidence and prev-
alence since this would lead to less new spending.
The weight of health economic evaluation and the
financial impact analysis in the decision-making
process need to be defined before formal require-
ments can be implemented.
Formal economic reporting requirements should
also describe the procedural framework within
which the pharmacoeconomic evaluation takes
place. It should be apparent in advance which
bodies are going to evaluate the pharmacoeco-
nomic analysis, whether there is an appeals proce-
dure, and what arrangements would be followed
for subsequent drugs within a therapeutic cluster
compared with the innovator (since costs for the
health economic evaluation of the innovative drug
are often much higher than for followers and also
to prevent free rides). Many questions need to be
answered. What are the procedures for submitting
a health economic study for reimbursement? Is it
possible to consult with the evaluator regarding
the composition of the health economic dossier?
Who is responsible for carrying out the research
and for financing it? What are the deadlines?
Which legal alternatives are available if a negative
decision is obtained? How will decisions be re-
viewed with new insights on the therapeutic value
and cost-effectiveness of a drug?
Finally I would like to consider the near future.
First, while opponents argue that drug registration
and reimbursement must be kept strictly separate,
there are signs that economic evaluation may soon
be part of the registration dossier in many Euro-
pean countries. Second, harmonization of guide-
lines and further moves towards Europe-wide de-
cisions on drug pricing and reimbursement are
likely, given the increasing interdependency of Eu-
ropean markets and regulatory authorities.
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